Ashermed Pharmaceutical Technology

Ashermed Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of nucleic acid therapeutics and advanced delivery systems. The company leverages its proprietary lipid nanoparticle (LNP) platform to design and manufacture a diverse range of mRNA vaccines and siRNA-based treatments. Its current pipeline features candidates targeting infectious diseases, such as COVID-19 and respiratory syncytial virus (RSV), as well as programs in oncology and metabolic disorders. Ashermed integrates robust research and development with internal manufacturing capabilities to accelerate the clinical translation of genetic medicines. The company aims to address significant unmet medical needs by optimizing the delivery and efficacy of next-generation biologics.